The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG125 – Paclitaxel
For use in combination with pertuzumab plus trastuzumab in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, and who are considered not fit enough for, or cannot tolerate docetaxel in this combination. (off-label use and off-patent medicine)
- Council meeting date: to be confirmed
- Planned publication date: to be confirmed
NCMAG 126 – Nivolumab plus ipilimumab
For use as neoadjuvant treatment of mismatch repair deficient or microsatellite instability‑high locally advanced colon cancer which is judged to be borderline resectable. (off-label use)
- Council meeting date: To be confirmed
- Planned publication date: To be confirmed